Sanofi has turned down the chance to opt into Alnylam’s primary hyperoxaluria type 1 drug lumasiran. The French pharma’s decision gives Alnylam control of a phase 3-ready rare disease drug with an FDA breakthrough therapy designation.
The makers of an expensive cholesterol-lowering drug plan to offer discounts of up to 69% in exchange for insurers and pharmacy-benefit managers expanding their coverage of the medicine to more patients.
ORLANDO, Fla.—As the American College of Cardiology's annual meeting kicked off in Orlando on Saturday, all eyes turned to Sanofi and Regeneron, who reported their PCSK9 drug Praluent reduced the risk of cardiovascular events by 15%—as well as...
The Dengvaxia mess in the Philippines is still actively evolving, but the vaccine’s maker Sanofi, with seemingly unyielding faith in its safety and efficacy, will soon decide whether to file for approval in the U.S.
Oops! Unable to complete your request. Please refresh your browser.